Federal Bid

Last Updated on 13 Jul 2021 at 4 PM
Combined Synopsis/Solicitation
Bethesda Maryland

Method development and determination of levels of (2R,6R)-hydroxynorketamine in human CSF

Solicitation ID 75N95021Q00126
Posted Date 13 Jul 2021 at 4 PM
Archive Date 28 Jul 2021 at 4 AM
NAICS Category
Product Service Code
Set Aside No Set-Aside Used
Contracting Office National Institutes Of Health Nida
Agency Department Of Health And Human Services
Location Bethesda Maryland United states 20892

THIS IS A NON-COMPETITIVE (NOTICE OF INTENT) COMBINED SYNOPSIS SOLICITATION TO AWARD A CONTRACT OR PURCHASE ORDER WITHOUT PROVIDING FOR FULL OR OPEN COMPETITION (INCLUDING BRAND-NAME).

The National Institute on Drug Abuse (NIDA), Office of Acquisition (OA), on behalf of the National Center for Advancing Translational Sciences (NCATS), intends to negotiate and award a purchase order without providing for full and open competition (including brand-name) to Covance Laboratories Inc., 3301 Kinsman Blvd, Madison, WI  53704-2523.  Covance Laboratories Inc. is performing other pharmacokinetics for this project, and to eliminate any variables and ensure the continuity of data, this pharmacokinetics requirement must also be completed by Covance Laboratories Inc.

DESCRIPTION: (2R,6R)-Hydroxynorketamine (2R,6R-HNK) is currently in phase 1 human clinical trials. NCATS needs to obtain the cerebrospinal fluid (CSF) levels of 2R,6R-HNK in order to determine if the compound is penetrating the blood brain barrier in human subjects.

See attached Request for Quotations, Statement of Work, and other attachments for complete requirement details.

Bid Protests Not Available